Newborn screening expansion is uneven across US states
RUSP additions tell only half the story - state-level implementation timelines stretch the diagnostic-to-treatment gap, and the variation has consequences for treatment-eligibility windows in time-sensitive rare disease.
The federal Recommended Uniform Screening Panel (RUSP) lists conditions that newborn screening programs should include. State adoption is a separate, slower process - some states implement within a year of a RUSP addition, others take three to five.
For rare diseases where treatment efficacy is gated on early diagnosis - several lysosomal storage disorders, certain neuromuscular conditions - this state-level variation determines who gets a usable diagnosis early enough to matter clinically. The gap is widest in conditions where a gene therapy or enzyme replacement product was approved in the past two years and has not yet been picked up by every state's NBS panel.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.